Director reviewArthrexPTAB procedure

PTAB Director review after Arthrex

By Ipiry TeamPublished August 25, 20267 min read

Short answer

Director review lets the USPTO Director review Board decisions in AIA proceedings. It exists because the Supreme Court held in Arthrex that unreviewable decisions by Administrative Patent Judges raised an Appointments Clause problem, and Director review is the remedy. Requests are made after a decision issues, and the process has become the principal route by which discretionary denial practice is set. The procedures have changed repeatedly, so check the current position.

PTAB Director review exists because of a constitutional problem, and it has become the main lever for setting Board policy.

In United States v. Arthrex, the Supreme Court held that Administrative Patent Judges issuing final decisions with no review by a properly appointed superior raised an Appointments Clause problem.

The remedy was review, not invalidation. Rather than unwinding the scheme, the Court's approach made Board decisions reviewable by the Director.

What followed has reshaped practice well beyond the constitutional question it was built to answer.

The problem it solves

	Before	After
Final written decisions	Unreviewable within the agency	Reviewable by the Director
Political accountability	Limited	Established
Appointments Clause issue	Present	Addressed
Federal Circuit appeal	Available	Still available

Director review is an agency-level process. It sits between the Board and the Federal Circuit rather than replacing either.

Two routes

Route	Detail
Party request	Filed after a decision issues
Director-initiated	Without any request

Director-initiated review has done the heavy lifting on policy. Issues of Board-wide importance have been addressed this way, which is faster than waiting for a suitable request.

Party requests are rarely granted. The process is not a general appeal, and routine disagreement with an outcome does not meet the bar.

What it has changed most

Area	Effect
Discretionary denial	The principal mechanism for setting policy
Parallel litigation treatment	Timing and duplication
Serial and parallel petitions	Multiple challenges to one patent
Consistency across panels	Board-wide direction
Real party in interest	Occasionally addressed

Discretionary denial is where this matters most. Whether the Board declines to institute, independent of the merits, determines whether a petition is ever evaluated. See PTAB discretionary denial.

Institution rates moved with it

Period	Approximate institution rate
October 2024	~65%
February 2026	~37%

Always quote an institution figure with its date. The framework has shifted substantially, and an undated rate is close to meaningless.

A strategy built on 2024 rates misjudges the present. That is the practical consequence for anyone planning a petition.

What a request typically addresses

Ground	Detail
An important issue of Board-wide significance	The main basis
Apparent error in the decision	Material, not disagreement
Inconsistency with precedent	Where panels diverge
Abuse of discretion	Institution decisions
Not general dissatisfaction	Denied

Most requests fail because they restate the losing argument. The process is not a second bite at the merits, and a request that does not identify why the issue matters beyond the parties will not succeed.

Authority

Source	Binds
Statute and rules	Everyone
Federal Circuit decisions	Everyone including the Board
Precedential decisions	Board panels
Director decisions, where designated	Board panels
Director decisions, undesignated	Substantial weight
Trial Practice Guide	Guidance only

Check the designation, not the source. A Director decision that has been designated precedential binds panels; one that has not still carries weight but is not binding in the same way. See PTAB precedential decisions.

The procedures have changed


Since Arthrex	Revised more than once
Interim processes	Have existed and been superseded
Scope of reviewable decisions	Adjusted
Request format and timing	Adjusted
Implication	Verify against current USPTO guidance

Anything written about this more than a year ago needs checking. The area has moved faster than most patent procedure, and secondary summaries describe the position at the time of writing.

The USPTO's PTAB pages are authoritative and free.

What it is not

Not	Why
A general appeal	Most requests are denied
A substitute for Federal Circuit review	Appeal remains available
A route to reargue the merits	Restating the loss fails
Available in ex parte reexamination	AIA proceedings only
Predictable	Grants are uncommon

Treat it as narrow. Building a strategy around obtaining Director review is building on an uncommon outcome.

Where it sits in a proceeding

Stage	Timing
Petition filed	Day 0
Preliminary response	~3 months
Institution decision	~6 months
Trial phase	Following institution
Final written decision	~12 months from institution
Director review request	After a decision issues
Federal Circuit appeal	After agency proceedings

A denied institution ends the proceeding, and that is where discretionary denial bites. The merits are never reached.

Which is why the procedural question comes first in any assessment of whether to file. See inter partes review.

Worked example: the same art, two eras

A petitioner considers challenging a patent with strong prior art.

	Filed 2024	Filed 2026
Prior art strength	Strong	Identical
Parallel litigation	Yes, trial 18 months out	Yes, trial 18 months out
Stipulation on overlapping grounds	Not offered	Offered
Framework at the time	More permissive	More restrictive
Institution likelihood	Higher	Materially lower

Nothing about the patent or the prior art changed. The framework did.

The stipulation in 2026 is doing work the 2024 filing did not need. Adapting to the current framework rather than the remembered one is the practical lesson.

A petitioner who assumed 2024 conditions would have filed without it.

Effect on strategy

Party	Consideration
Petitioner	Time the filing against the current framework
Petitioner	Offer stipulations on overlapping grounds
Patent owner	Procedural arguments before substantive ones
Both	Watch parallel trial dates
Buyers	A survived challenge changes the asset

Patent owners now lead with procedure. A discretionary denial ends the proceeding without the prior art ever being evaluated, which is a better outcome than winning on the merits.

Timing

Point	Detail
Request follows a decision	Not before
Time limit	Short, set by current procedures
Director-initiated	No party trigger needed
Effect on appeal deadlines	Check current guidance

The window is short. Missing it forecloses the route, so the deadline goes in the calendar when the decision issues rather than when someone gets to it.

What to watch

Signal	Why
New Director decisions	Policy moves here first
Designation changes	What binds panels
Procedural revisions	How to file
Board institution statistics	The observable effect
Federal Circuit review of the framework	Can override

Check the precedential list quarterly rather than relying on citations found elsewhere. It takes minutes and it is free. See patent litigation updates.

Before it becomes relevant

Check	Why
Is the patent in force?	58.6% are abandoned before term
Are the grounds available in IPR?	§101 and §112 are not
What does estoppel cost you?	Filing has consequences
Is there a cheaper answer?	Design-around, licence, waiting

Ipiry Patent Survival Curve v1.0	Rate
Survive the 3.5-year fee (2022 cohort)	85.8%
Survive the 7.5-year fee (2018 cohort)	64.6%
Reach full term (2014 cohort)	41.4%
Lost at the third fee	23.2 points

Computed from 27,273,654 USPTO maintenance fee records covering 8,262,336 US utility patents — see the patent survival curve.

Waiting is sometimes the answer. A patent approaching its third maintenance fee has a 23.2-point chance of being released at that window, which is cheaper than any proceeding.

PTAB Director review: the checklist

Understand why it exists. Arthrex required reviewability, not invalidation.
Note both routes — party request and Director-initiated.
Do not treat it as an appeal. Most requests are denied.
Watch it for discretionary denial policy, which is set here.
Check designations, since not every decision binds panels.
Verify current procedures at the USPTO. They have changed repeatedly.
Date every institution statistic you rely on.
Adapt filing strategy to the current framework, not a remembered one.
Remember Federal Circuit appeal remains available after agency proceedings.
Check the patent is in force before planning any challenge.

Common questions

What is Director review?

A process allowing the Director of the USPTO to review decisions of the Patent Trial and Appeal Board in AIA proceedings. It provides political accountability over Board decisions that were previously unreviewable within the agency.

Why does it exist?

Because of United States v. Arthrex, in which the Supreme Court held that Administrative Patent Judges issuing final decisions with no superior review raised an Appointments Clause problem. Director review was the remedy adopted rather than invalidating the scheme.

What decisions can be reviewed?

Decisions in AIA proceedings, including final written decisions and institution decisions. The scope has been adjusted through successive procedural changes, so the current position should be checked rather than assumed from an older description.

How do I request it?

By filing a request within the time and format the USPTO's current procedures specify, after the decision issues. The request identifies why review is warranted, and the procedures have been revised more than once since the process began.

Is review granted often?

No. Most requests are denied, and the process is not a general appeal. It targets decisions raising important issues or apparent error rather than routine disagreement with an outcome.

Can the Director act without a request?

Yes. The Director may initiate review independently, and this route has been used to address issues of Board-wide importance, particularly in discretionary denial practice.

Does it replace appealing to the Federal Circuit?

No. Appeal to the Federal Circuit remains available for final written decisions. Director review is an agency-level process that occurs first and can affect what is ultimately appealed.

Why does it matter so much for discretionary denial?

Because Director decisions have become the main mechanism for setting discretionary denial policy. That framework determines whether petitions are considered on their merits at all, which affects outcomes more than most substantive arguments.

Do Director decisions bind the Board?

Decisions issued through the process carry substantial weight, and those designated precedential bind Board panels. Checking the designation matters, because not every decision carries the same authority.

Has the process changed since it started?

Repeatedly. The scope, procedures and the role of an interim process have all been adjusted since Arthrex. Anything written about it more than a year ago should be verified against the current USPTO guidance.

Should I factor it into a filing strategy?

Yes, at least by watching it. Institution rates have shifted substantially as this practice has developed, and a strategy built on rates from two years ago may misjudge the likelihood of institution entirely.

Where do I find current information?

The USPTO's PTAB pages, which publish the current procedures and the list of precedential and informative decisions. That is the authoritative source, and secondary summaries lag it.

PTAB: the Patent Trial and Appeal Board

What the PTAB is, the proceedings it hears, who the judges are, how a trial runs, what it costs, and why institution rates have moved so sharply.

PTAB precedential decisions: how the precedent works

How PTAB decisions become binding — the designation process, informative versus precedential, Director review, and where to find what currently governs.

PTAB discretionary denial

Why the PTAB declines to institute petitions that meet the merits threshold — parallel litigation, serial petitions, previously considered art — and what the shifting rates mean in practice.

What is your patent worth?

Free AI valuation in 60 seconds, benchmarked against 652,000 KPSS patent value records and the Ipiry Patent Survival Curve.

Value My Patent Free →Takes 60 seconds. No credit card required.